Xeltis

Xeltis

Developing new heart valves and coronary artery bypass grafts (cabgs) made from patients' own tissue.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor investor

€0.0

round
investor investor investor

€0.0

round
investor investor investor

€0.0

round
investor

€0.0

round
investor investor investor investor

€0.0

round
investor investor investor investor investor

€0.0

Valuation: €0.0

round
investor

€0.0

round
investor

€0.0

Valuation: €0.0

round
investor

€0.0

Valuation: €0.0

round
investor investor investor investor

€0.0

Valuation: €0.0

round
*

€12.5m

Valuation: €225m

Series D
Total Funding000k
More about Xeltis
Made with AI
Edit

Developer of medical devices designed to provide a restorative approach to cardiovascular therapy. The company's device comprises bioabsorbable heart valves and blood vessels designed to allow endogenous tissue restoration which is the natural restoration of the complex body part that gets replaced upon implantation, enabling the patient's body to naturally restore a new blood vessel or heart valve through a therapeutic approach.

Keywords: Healthcare Devices, Services, Supplies, Biodegradable Heart Valve, Coronary Bypass, Dialysis Access, Endogenous Tissue Growth, Heart Surgery, Medical Device, Medical Device Company, Vascular Disease Treatment, Vascular Surgery.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Xeltis

Edit
Qtis/e
ACQUISITION by Xeltis 2012